Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.56 |
| ▸ | NOS1 | P29475 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 3/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266433 | 0.83 | SCN8A (0.65) | SCN8ANOS1KDM1AMAOAMAOB | |
| SCHEMBL320058 | 0.83 | LOXL2 (0.59) | SCN8ANOS1KDM1AMAOAMAOB | |
| SCHEMBL30471916 | 0.83 | LOXL2 (0.59) | SCN8ANOS1KDM1AMAOAMAOB | |
| SCHEMBL11922712 | 0.82 | SCN8A (0.64) | SCN8ANOS1MAOADPP7HRH3 | |
| SCHEMBL5909429 | 0.80 | PARP1 (0.47) | CYP19A1CYP1A2CYP2D6MAPTCYP2C19 | |
| SCHEMBL4934435 | 0.79 | GLA (0.51) | SCN8AGLAMEP1AMEP1BCYP19A1 | |
| SCHEMBL25588020 | 0.79 | KDM1A (0.51) | SCN8ANOS1KDM1AMAOAMAOB | |
| SCHEMBL410123 | 0.79 | SCN8A (0.57) | SCN8ANOS1KDM1AMAOAMAOB | |
| SCHEMBL2772974 | 0.79 | SCN8A (0.64) | SCN8ANOS1KDM1AMAOAMAOB | |
| SCHEMBL126485 | 0.79 | CYP2A6 (0.56) | SCN8AKDM1AMAOAMAOBGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
| US-10772892-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2020-09-15 | — | — | US | disclosed |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| WO-2017191098-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-09 | — | — | WO | disclosed |
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| EP-2414342-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
| CN-102803238-B | Oxadiazole Derivatives | MERCK SERONO S.A. (CH) | 2015-09-30 | — | — | CN | disclosed |
| US-8815919-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8802704-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| CN-102803238-A | Oxadiazole derivatives | MERCK SERONO SA | 2012-11-28 | — | — | CN | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| EP-2414341-A2 | OXADIAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| EP-2414342-A1 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2010115751-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010112461-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | FUT6, DDOST, MGAM | SCN8A 2438/4885NOS1 3624/4885KDM1A 2041/4885 |
| US-10772892-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | SCN8A 3758/4885NOS1 4773/4885KDM1A 373/4885 |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | SCN8A 4099/4885NOS1 1169/4885KDM1A 1720/4885 |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | SCN8A 2544/4885NOS1 386/4885KDM1A 1673/4885 |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | SCN8A 2544/4885NOS1 386/4885KDM1A 1673/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | SCN8A 3771/4885NOS1 4751/4885KDM1A 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.